Welcome to our dedicated page for Iqvia Hldgs news (Ticker: IQV), a resource for investors and traders seeking the latest updates and insights on Iqvia Hldgs stock.
IQVIA Holdings Inc. (IQV) delivers integrated healthcare insights through its unique combination of clinical research expertise and advanced data analytics. This news hub provides investors and industry professionals with timely updates on corporate developments shaping the life sciences sector.
Access official press releases and curated news coverage spanning clinical trial milestones, healthcare data partnerships, regulatory updates, and technology innovations. Our collection serves as a strategic resource for understanding IQVIA's role in optimizing drug development cycles and commercial decision-making.
Key content categories include earnings announcements, merger/acquisition activity, leadership changes, and analytical breakthroughs in real-world evidence applications. Bookmark this page for efficient tracking of IQVIA's progress in transforming clinical research through data-driven solutions.
IQVIA announced its innovative approach, Connected Intelligence, aimed at enhancing insights and decision-making in the life sciences sector. This strategy integrates IQVIA’s extensive healthcare data, advanced analytics, and technologies to facilitate faster drug development. Key initiatives include:
- Accelerating over 350 clinical research studies for COVID-19.
- Supporting 60 decentralized clinical trials in 40 countries.
- Linking real-world data for disease understanding and drug discovery.
IQVIA aims to improve societal health outcomes through innovation and significant investments in the healthcare ecosystem.
IQVIA Holdings Inc. reported a strong first quarter of 2021 with revenues of $3,409 million, marking a 23.8% increase year-over-year. Technology & Analytics Solutions revenue grew by 20.7%, while Research & Development Solutions surged by 29.6%. The company's backlog reached $23.2 billion, with expectations to convert approximately $6.5 billion to revenue in the next year. Adjusted EBITDA rose to $744 million, up 32.4%. As a result, IQVIA raised its full-year guidance for revenue and earnings per share, projecting significant growth driven by continued demand in life sciences.
IQVIA Holdings Inc. (NYSE:IQV) will release its first-quarter 2021 financial results on April 22, 2021, before the market opens. A conference call and webcast led by the management team will take place at 9:00 a.m. ET on the same day. Investors can access the earnings release on the IQVIA Investor Relations website. IQVIA is a global leader in analytics and technology solutions for the life sciences industry, employing approximately 70,000 individuals across 100 countries.
Moleculin Biotech, Inc. (Nasdaq: MBRX) has partnered with IQVIA Biotech to initiate clinical trials for WP1122, a drug aimed at treating COVID-19. The decision stems from delays in obtaining FDA approval due to the unavailability of validated COVID-19 animal models in the U.S. However, the company believes it has completed necessary preclinical testing to qualify for foreign IND submission. WP1122 is designed to enhance the drug-like properties of 2-deoxy-D-glucose (2-DG), which has shown efficacy against SARS-CoV-2.
Quest Diagnostics (NYSE: DGX) has announced the sale of its minority share in Q2 Solutions to IQVIA (NYSE: IQV) for $760 million in cash. This divestiture aligns with Quest's strategy to focus on diagnostic information services. Since 2015, Q2 Solutions operated as a joint venture, with IQVIA owning 60% and Quest 40%. Despite the sale, Quest will remain the preferred laboratory provider for Q2 Solutions under a multi-year agreement, allowing them to continue offering complementary lab testing services.
IQVIA Holdings Inc. (NYSE:IQV) has completed the acquisition of Quest Diagnostics' 40% minority share in Q2 Solutions for $760 million. This acquisition provides IQVIA full ownership, enhancing its capabilities in clinical laboratory services. The transaction is cash-funded, maintaining IQVIA's target net leverage ratio. The acquisition is expected to be accretive to IQVIA's Adjusted Diluted EPS, with revised guidance for 2021 set between $7.89 and $8.20. This move strengthens IQVIA's market position and service offerings while ensuring Quest remains a key laboratory partner.
IQVIA (NYSE:IQV) has reported that over 60 clinical trials across 40 countries are now utilizing its advanced decentralized clinical trial solutions. These trials, initiated in 2020, offer flexible and patient-centric alternatives during the pandemic. By focusing on patient-centricity, IQVIA aims to integrate trials seamlessly into patients' lives, thereby easing the burden on participants and investigators. The company supports these trials with various technologies, including telehealth and home health nursing, enrolling over 150,000 subjects across multiple therapeutic areas, including COVID-19 and oncology.
IQVIA announced its collaboration with Janssen Research & Development since September 2020 for Phase 3 COVID-19 vaccine clinical trials. The trials utilize IQVIA’s decentralized trial solutions, allowing remote screening and data reporting via telehealth technologies. This approach enhances participant engagement and facilitates efficient study delivery. With approximately 70,000 employees operating in over 100 countries, IQVIA positions itself as a leader in advanced analytics, technology solutions, and clinical research services within the life sciences sector.
IQVIA Holdings Inc. (NYSE:IQV) announced that CFO Ron Bruehlman will participate in a virtual fireside chat at the Barclays Global Healthcare Conference on March 09, 2021, at 3:00 p.m. EST. The event will be accessible via live audio webcast on the IQVIA Investor Relations website, with a replay available later that day. IQVIA is a global leader in advanced analytics, technology solutions, and clinical research for the life sciences sector, employing around 70,000 staff across over 100 countries.
IQVIA Holdings Inc. (NYSE:IQV) announced the pricing of an offering of €1.45 billion in senior notes. This includes €550 million due in 2026 and €900 million due in 2029. Proceeds will be utilized to redeem outstanding 3.250% senior notes due 2025 and cover related expenses. The 2026 Notes carry a 1.750% interest rate, while the 2029 Notes have a 2.250% rate, both paying interest semi-annually. The offering is expected to close around March 3, 2021, contingent on standard conditions. These notes will not be registered under the Securities Act.
